← 返回

Gasdermin 介导的细胞焦亡:抗结直肠癌的新策略

英文原题:Gasdermin-Mediated Pyroptosis: Novel Strategies Against Colorectal Cancer.

查看英文原题

Gasdermin-Mediated Pyroptosis: Novel Strategies Against Colorectal Cancer.

PubMed 2026/05/28(内容时间) Cancer Sci Q2 · IF 4.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

细胞焦亡是一种由gasdermin蛋白介导的程序性细胞死亡形式,因其在结直肠癌(CRC)进展和治疗中的双重作用而受到关注。虽然慢性细胞焦亡驱动的炎症可促进肿瘤发生,但肿瘤细胞中细胞焦亡的急性诱导可提供有前景的抗肿瘤效应。理解细胞焦亡在CRC中的机制和意义可能带来新的治疗策略。Gasdermin蛋白,尤其是GSDMD和GSDME,是CRC中细胞焦亡过程的核心。GSDMD激活通常通过NLRP3炎症小体信号通路或辛伐他汀等化疗药物实现,可诱导细胞焦亡并调节免疫浸润。相反,GSDMC已被认为在代谢应激下通过招募免疫抑制细胞参与CRC进展。尽管GSDME在CRC中经常被沉默,但它可增强对放化疗的敏感性,并通过释放免疫刺激分子与免疫检查点抑制剂产生协同作用。

炎症小体,特别是NLRP3和AIM2,也通过细胞焦亡和细胞因子分泌在CRC发病机制中发挥重要作用。NLRP3激活通过炎症通路加剧肿瘤生长,而AIM2则发挥肿瘤抑制作用,尤其是在BRAF突变型CRC中。肠道微生物群进一步影响炎症小体活性,某些菌株促进化疗耐药,而另一些则增强抗肿瘤免疫。在治疗方面,诱导细胞焦亡可与常规疗法和免疫疗法产生协同作用,克服凋亡抵抗并使肿瘤重新敏感化。细胞焦亡释放肿瘤抗原和损伤相关分子模式,招募细胞毒性淋巴细胞和NK 细胞,从而重塑免疫抑制微环境。细胞焦亡在CRC中是一把双刃剑,既带来挑战也带来机遇。利用其抗肿瘤潜力,同时减轻促肿瘤炎症,需要创新策略。未来的研究应聚焦于阐明gasdermins的异构体特异性作用,优化诱导细胞焦亡的治疗方法。

展开英文摘要原文

Pyroptosis, a form of programmed cell death mediated by gasdermin proteins, has gained attention for its dual role in colorectal cancer (CRC) progression and therapy. While chronic pyroptosis-driven inflammation can promote tumorigenesis, acute induction of pyroptosis in tumor cells offers promising antitumor effects. Understanding the mechanisms and implications of pyroptosis in CRC could lead to novel therapeutic strategies. Gasdermin proteins, particularly GSDMD and GSDME, are central to pyroptotic processes in CRC. GSDMD activation, often through NLRP3 inflammasome signaling or chemotherapeutic agents like simvastatin, induces pyroptosis and modulates immune infiltration. Conversely, GSDMC has been implicated in CRC progression under metabolic stress by recruiting immunosuppressive cells. Although frequently silenced in CRC, GSDME enhances sensitivity to chemoradiation and synergizes with immune checkpoint inhibitors by releasing immunostimulatory molecules. Inflammasomes, notably NLRP3 and AIM2, also play significant roles in CRC pathogenesis through pyroptosis and cytokine secretion.

NLRP3 activation exacerbates tumor growth via inflammatory pathways, while AIM2 exerts tumor-suppressive effects, especially in BRAF-mutant CRC. The gut microbiota further influences inflammasome activity, with certain strains promoting chemoresistance and others enhancing antitumor immunity. Therapeutically, inducing pyroptosis synergizes with conventional therapies and immunotherapies, overcoming apoptosis resistance and resensitizing tumors.

Pyroptosis releases tumor antigens and damage-associated molecular patterns, recruiting cytotoxic lymphocytes and natural killer cells, thereby remodeling the immunosuppressive microenvironment. Pyroptosis represents a double-edged sword in CRC, offering both challenges and opportunities. Harnessing its antitumor potential while mitigating pro-tumorigenic inflammation requires innovative strategies. Future research should focus on elucidating the isoform-specific roles of gasdermins, optimizing therapeutic approaches to induce pyroptosis.

论文信息

作者
Guo K、Feng Y、Lu J、Abudurexiti N、Zhou X、Wei M、Zheng S
单位
Department of Oncology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.China
文献类型
综述
期刊
Cancer science2026 Aug
原文标识
PubMed 42206417 · DOI 10.1111/cas.70426